[go: up one dir, main page]

UA106076C2 - Спосіб посилення імунної реакції у видів птахів та композиція для цього - Google Patents

Спосіб посилення імунної реакції у видів птахів та композиція для цього

Info

Publication number
UA106076C2
UA106076C2 UAA201114824A UAA201114824A UA106076C2 UA 106076 C2 UA106076 C2 UA 106076C2 UA A201114824 A UAA201114824 A UA A201114824A UA A201114824 A UAA201114824 A UA A201114824A UA 106076 C2 UA106076 C2 UA 106076C2
Authority
UA
Ukraine
Prior art keywords
avian species
composition
immune activation
infectious disease
effective
Prior art date
Application number
UAA201114824A
Other languages
English (en)
Russian (ru)
Inventor
Альберт Абрахам
Original Assignee
Баєр Інтеллекчуел Проперті Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Баєр Інтеллекчуел Проперті Гмбх filed Critical Баєр Інтеллекчуел Проперті Гмбх
Publication of UA106076C2 publication Critical patent/UA106076C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Винахід належить до способу викликання неспецифічної до антигену імунної реакції у представника пташиного виду для його захисту від інфекційної хвороби та лікування, що включає введенняабо аерозольним шляхом представникові пташиного виду композиції, яка містить:a) катіонний ліпосомний носій; таb) виділений з бактерії нуклеїновокислотний вектор без генної вставки.
UAA201114824A 2009-05-14 2010-05-07 Спосіб посилення імунної реакції у видів птахів та композиція для цього UA106076C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17809909P 2009-05-14 2009-05-14
PCT/EP2010/002809 WO2010130374A1 (en) 2009-05-14 2010-05-07 Enhanced immune response in avian species

Publications (1)

Publication Number Publication Date
UA106076C2 true UA106076C2 (uk) 2014-07-25

Family

ID=42357738

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201114824A UA106076C2 (uk) 2009-05-14 2010-05-07 Спосіб посилення імунної реакції у видів птахів та композиція для цього

Country Status (34)

Country Link
US (1) US20120064151A1 (uk)
EP (2) EP2429581B1 (uk)
JP (1) JP5679589B2 (uk)
KR (2) KR101966989B1 (uk)
CN (2) CN104906573A (uk)
AR (1) AR076767A1 (uk)
AU (1) AU2010246652B2 (uk)
BR (1) BRPI1010803A2 (uk)
CA (1) CA2761736C (uk)
CL (1) CL2011002808A1 (uk)
CO (1) CO6460752A2 (uk)
CR (1) CR20110595A (uk)
DK (2) DK2429581T3 (uk)
EC (1) ECSP11011448A (uk)
ES (2) ES2808827T3 (uk)
HR (2) HRP20151117T1 (uk)
HU (2) HUE051005T2 (uk)
IL (1) IL215900A (uk)
LT (1) LT2992899T (uk)
MX (1) MX336019B (uk)
MY (1) MY162561A (uk)
NI (1) NI201100196A (uk)
NZ (1) NZ596366A (uk)
PE (1) PE20120903A1 (uk)
PL (2) PL2992899T3 (uk)
PT (2) PT2429581E (uk)
RU (1) RU2570732C9 (uk)
SI (2) SI2429581T1 (uk)
SV (1) SV2011004056A (uk)
TW (1) TWI555846B (uk)
UA (1) UA106076C2 (uk)
UY (1) UY32634A (uk)
WO (1) WO2010130374A1 (uk)
ZA (1) ZA201107827B (uk)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2257306B1 (en) * 2008-03-25 2014-05-07 Juvaris Biotherapeutics, Inc. Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc)
MX345854B (es) * 2010-12-22 2017-02-17 Bayer Ip Gmbh Respuesta inmune potenciada en la especie bovina.
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
CN103721253B (zh) * 2014-01-02 2015-06-10 青岛易邦生物工程有限公司 一种禽脑脊髓炎和鸡痘二联活疫苗
MX2016010993A (es) 2014-02-28 2017-05-01 Bayer Animal Health Gmbh Plasmidos inmunoestimuladores.
US9814769B2 (en) 2014-09-30 2017-11-14 Qatar University Vaccines against pathogenic Escherichia coli and methods of using the same
JP2018518511A (ja) * 2015-06-26 2018-07-12 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｇｍｂｈ 細胞質ｄｎａ監視分子の調節方法
TW201718001A (zh) * 2015-07-31 2017-06-01 拜耳動物保健有限公司 豬物種中增強之免疫反應
WO2017021242A1 (en) * 2015-07-31 2017-02-09 Bayer Animal Health Gmbh Enhanced immune response in aquatic species
US10933131B2 (en) 2016-07-26 2021-03-02 Bayer Animal Health Gmbh Increased fertility in bovine species
WO2019115386A1 (en) * 2017-12-15 2019-06-20 Bayer Animal Health Gmbh Immunostimulatory oligonucleotides
CN114467855A (zh) * 2022-01-14 2022-05-13 广东海大集团股份有限公司 一种多病因气囊炎雏鸡模型的构建方法及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4458630A (en) * 1982-06-22 1984-07-10 The United States Of America As Represented By The Secretary Of Agriculture Disease control in avian species by embryonal vaccination
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5427791A (en) 1992-08-05 1995-06-27 Regents Of The University Of Minnesota Embryonal vaccine against Newcastle disease
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6048535A (en) 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
ATE272410T1 (de) * 1999-03-26 2004-08-15 Vical Inc Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
US7355092B2 (en) * 1999-12-27 2008-04-08 Ronald Marquardt Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic Escherichia coli and other pathogens
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
EP2257306B1 (en) * 2008-03-25 2014-05-07 Juvaris Biotherapeutics, Inc. Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc)

Also Published As

Publication number Publication date
CN104906573A (zh) 2015-09-16
HUE025765T2 (en) 2016-05-30
US20120064151A1 (en) 2012-03-15
AR076767A1 (es) 2011-07-06
RU2570732C9 (ru) 2016-09-10
CA2761736A1 (en) 2010-11-18
EP2429581A1 (en) 2012-03-21
DK2429581T3 (en) 2015-11-09
CN102427827B (zh) 2015-07-22
CR20110595A (es) 2012-03-09
HRP20151117T1 (hr) 2015-11-20
NZ596366A (en) 2013-12-20
PL2429581T3 (pl) 2016-01-29
PE20120903A1 (es) 2012-08-01
HRP20201554T1 (hr) 2020-12-11
AU2010246652A1 (en) 2011-11-17
CN102427827A (zh) 2012-04-25
WO2010130374A1 (en) 2010-11-18
KR20170102379A (ko) 2017-09-08
CA2761736C (en) 2017-09-26
IL215900A0 (en) 2012-01-31
HK1168032A1 (zh) 2012-12-21
RU2011150529A (ru) 2013-06-20
ES2808827T3 (es) 2021-03-02
ZA201107827B (en) 2012-12-27
MY162561A (en) 2017-06-30
RU2570732C2 (ru) 2015-12-10
DK2992899T3 (da) 2020-09-14
PT2992899T (pt) 2020-09-21
KR101966989B1 (ko) 2019-04-08
EP2429581B1 (en) 2015-08-05
CL2011002808A1 (es) 2012-07-13
JP2012526734A (ja) 2012-11-01
EP2992899A1 (en) 2016-03-09
ECSP11011448A (es) 2011-12-30
UY32634A (es) 2010-12-31
ES2550181T3 (es) 2015-11-05
SV2011004056A (es) 2012-03-14
EP2992899B1 (en) 2020-07-01
PL2992899T3 (pl) 2021-04-06
TWI555846B (zh) 2016-11-01
MX2011011931A (es) 2011-12-06
NI201100196A (es) 2012-06-06
PT2429581E (pt) 2015-11-02
MX336019B (es) 2016-01-06
SI2992899T1 (sl) 2020-10-30
LT2992899T (lt) 2020-10-26
HUE051005T2 (hu) 2021-01-28
AU2010246652B2 (en) 2014-10-02
TW201043698A (en) 2010-12-16
KR20120027345A (ko) 2012-03-21
JP5679589B2 (ja) 2015-03-04
SI2429581T1 (sl) 2015-11-30
IL215900A (en) 2017-07-31
CO6460752A2 (es) 2012-06-15
BRPI1010803A2 (pt) 2018-06-12

Similar Documents

Publication Publication Date Title
UA106076C2 (uk) Спосіб посилення імунної реакції у видів птахів та композиція для цього
MY167159A (en) Enhanced immune response in bovine species
BRPI1007476A2 (pt) análogos de ciclosporina para prevenir ou tratar infecção por hepatite c
ZA200802892B (en) Vaccines and methods to treat canine influenza
PH12014502875A1 (en) Vaccine compositions for prevention against dengue virus infection
MY168959A (en) Vaccine compositions for the prevention of dengue virus infection
IN2014CN03925A (uk)
BRPI1008561A2 (pt) vacinas vivas atenuadas
CL2013001475A1 (es) Proceso de tratamiento de productos vegetales antes o despues de la cosecha con acido fosfonico y un aceite esencial; composicion que comprende acido fosfonico y aceite esencial.
MX2018002926A (es) Composiciones contra alergia a los gatos.
MX2022015141A (es) Composiciones y metodos de uso de un compuesto de control de inapetencia.
PH12018500201A1 (en) Enhanced immune response in porcine species
CL2012002654A1 (es) Compuesto de propilmetilfenol o una composicion que lo comprende para tratar septicemia rickettsial salmonidea (srs) y/o enfermedades causadas por la piscirickettsia salmonis.
CL2012003219A1 (es) Parapoxvirus recombinante que comprende un parapoxvirus y adn heterólogo derivado de un virus de la rabia; procedimiento de preparación de dicho parapoxvirus; composicion inmunogénica; uso de la composicion para inducir respuesta inmunitaria contra el virus de la rabia en un animal.
UA106490C2 (uk) Застосування пропінебу як репеленту для птахів
WO2011140226A3 (en) Compositions comprising extracts of southernwood and an amine compound
WO2009117736A3 (en) Avian virus vaccines and uses thereof
EP2195019A4 (en) METHOD FOR TRIGGERING AN IMMUNE RESPONSE AGAINST THE PANDEMIC INFLUENZA VIRUS
ZA201205639B (en) Compositions and methods for treating hepatitis b virus infection
WO2011096685A3 (ko) 신종플루 바이러스와 조류인플루엔자 바이러스에 대한 불활화능을 가진 약쑥 95%주정추출물이 함유된 쑥환
NI201300058A (es) Respuesta inmune potenciada en la especie bovina
WO2014059160A3 (en) Plant species that are an effective treatment for viral infections in animals and plants
AU2010101160A4 (en) Device to remove foxes and wild dogs from humans
WO2012128508A3 (ko) 광견병 바이러스를 중화시킬 수 있는 결합 분자
GB201223169D0 (en) Method of treating tree or plant disease